IRIS
FUMAROLA, Claudia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.965
EU - Europa 2.886
AS - Asia 1.711
SA - Sud America 310
AF - Africa 56
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 1
Totale 7.934
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.927
IT - Italia 756
CN - Cina 686
SG - Singapore 557
IE - Irlanda 443
FI - Finlandia 410
SE - Svezia 385
DE - Germania 284
BR - Brasile 280
HK - Hong Kong 214
UA - Ucraina 127
NL - Olanda 109
TR - Turchia 76
FR - Francia 72
GB - Regno Unito 64
IN - India 64
AT - Austria 54
RU - Federazione Russa 54
BE - Belgio 49
CI - Costa d'Avorio 40
CA - Canada 33
CZ - Repubblica Ceca 20
ID - Indonesia 18
VN - Vietnam 15
PL - Polonia 14
AR - Argentina 11
EC - Ecuador 9
PK - Pakistan 9
PS - Palestinian Territory 9
BD - Bangladesh 7
IR - Iran 7
JP - Giappone 7
ES - Italia 6
IQ - Iraq 6
UZ - Uzbekistan 6
LT - Lituania 5
LU - Lussemburgo 5
ZA - Sudafrica 5
HU - Ungheria 4
KG - Kirghizistan 4
NZ - Nuova Zelanda 4
PT - Portogallo 4
AE - Emirati Arabi Uniti 3
AL - Albania 3
AZ - Azerbaigian 3
CH - Svizzera 3
CO - Colombia 3
JO - Giordania 3
KE - Kenya 3
KR - Corea 3
LB - Libano 3
MA - Marocco 3
MX - Messico 3
NP - Nepal 3
RO - Romania 3
VE - Venezuela 3
CY - Cipro 2
EE - Estonia 2
EG - Egitto 2
MD - Moldavia 2
NO - Norvegia 2
AU - Australia 1
BG - Bulgaria 1
BH - Bahrain 1
BO - Bolivia 1
BY - Bielorussia 1
CL - Cile 1
GA - Gabon 1
GR - Grecia 1
HR - Croazia 1
IL - Israele 1
JM - Giamaica 1
KZ - Kazakistan 1
LV - Lettonia 1
NI - Nicaragua 1
PE - Perù 1
PY - Paraguay 1
SI - Slovenia 1
SN - Senegal 1
SY - Repubblica araba siriana 1
TJ - Tagikistan 1
TN - Tunisia 1
TW - Taiwan 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 7.934
Salva come PNG Salva come JPEG
Città #
Dublin 443
Chandler 408
Singapore 343
Ann Arbor 338
Ashburn 273
Santa Clara 266
Parma 238
Hong Kong 212
Dearborn 155
Jacksonville 144
Boardman 122
Beijing 116
Shanghai 100
Munich 93
Nanjing 84
New York 78
Princeton 67
Izmir 65
Bremen 61
Milan 61
Helsinki 49
Hefei 46
Vienna 46
Abidjan 40
Nanchang 40
San Mateo 40
Los Angeles 38
Shenyang 37
Chicago 36
Wilmington 34
Brussels 31
Moscow 31
Columbus 30
Kunming 28
Modena 28
Hebei 27
São Paulo 25
The Dalles 24
Jinan 23
Marseille 23
Des Moines 22
Council Bluffs 20
Redmond 20
Seattle 20
Turku 20
Jakarta 18
Tianjin 18
Nuremberg 17
Toronto 17
Woodbridge 17
Bologna 16
Dallas 16
Pune 15
Norwalk 14
Reggio Emilia 14
Amsterdam 13
London 13
Brescia 12
Frankfurt am Main 12
Jiaxing 12
Neviano degli Arduini 12
Wayne 12
Bari 11
Changsha 11
Leawood 11
Florence 10
Fremont 10
Guangzhou 10
Rio de Janeiro 10
Gaza 9
Rome 9
Bengaluru 8
Dong Ket 8
Fuzhou 8
Grafing 8
Manchester 8
Verona 8
Ardabil 7
Augusta 7
Binche 7
Brasília 7
Campinas 7
Leuven 7
Montreal 7
Warsaw 7
Zhengzhou 7
Brno 6
Chengdu 6
Contagem 6
Düsseldorf 6
Fairfield 6
Follonica 6
Monmouth Junction 6
Redwood City 6
Salsomaggiore Terme 6
Boston 5
Genoa 5
Luxembourg 5
Ningbo 5
Phoenix 5
Totale 4.974
Salva come PNG Salva come JPEG
Nome #
Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR 237
Efficacy of the cdk4/6 dual inhibitor abemaciclib in egfr-mutated nsclc cell lines with different resistance mechanisms to osimertinib 168
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC 152
Pemetrexed enhances membrane PD-L1 expression and potentiates T cell-mediated cytotoxicity by anti-PD-L1 antibody therapy in non-small-cell lung cancer 145
Dual inhibition of CDK4/6 and PI3K/AKT/mTOR signaling impairs energy metabolism in MPM cancer cells 144
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines. 139
Characterization of gefitinib uptake in NSCLC cell lines 138
Cell size reduction induced by inhibition of the mTOR/S6K signaling pathway protects Jurkat cells from apoptosis 136
Dose-dependent effect of FHIT-inducible expression in Calu-1 lung cancer cell line 135
Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines 134
PD-L1 overexpression induces STAT signaling and promotes the secretion of pro-angiogenic cytokines in non-small cell lung cancer (NSCLC) 132
Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism. 131
Novel activity of a synthetic decapeptide against Toxoplasma gondii Tachyzoites 127
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance 126
Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells. 124
Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification 123
Targeting PI3K somatic mutations reduces invasion and EMT in squamous cell carcinoma of the lung 123
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations. 122
Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer 122
Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models 119
Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines 115
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines 115
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation 115
Anti-proliferative effect of letrozole and sorafenib in MCF-7/AROM-1 breast cancer cells 115
Anti-proliferative effect of combining Letrozole with Sorafenib in MCF-7/Arom-1 breast cancer cells 114
Antiproliferative and proapototic effects of a new combi-molecule on non small cell lung cancer cell lines 111
Creatine as a compatible osmolyte in muscle cells exposed to hypertonic stress 109
Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines 108
Meccanismo d’azione di UPR 1024: un nuovo farmaco con attività antiproliferativa in cellule di carcinoma polmonare umano 107
Effect of specific PI3K/mTOR inhibitors in squamous lung cancer cells carrying PI3K alterations 106
Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines 105
CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells 105
Anti-proliferative and pro-apoptotic effects of Sorafenib in breast cancer cells in vitro. 104
Physico-chemical characterization and biological evaluation of two fibroin materials 103
CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells 102
Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN 102
Changes in glucose uptake after erlotinib treatment in NSCLC cell lines: a predictive and prognostic value? 101
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. (Cavazzoni and Bonelli co-first authors) 99
Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion 96
Effect of inducible FHIT and p53 expression in the Calu-1 lung cancer cell line 96
A Photoactive Supramolecular Complex Targeting PD-L1 Reveals a Weak Correlation between Photoactivation Efficiency and Receptor Expression Levels in Non-Small-Cell Lung Cancer Tumor Models 95
Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK-mTORC1 signaling 95
Anti-proliferative effects of copper(II) complexes with hydroxyquinoline-thiosemicarbazone ligands 94
CDK4/6 INHIBITORS AS A NEW THERAPEUTIC APPROACH IN MESOTHELIOMA MODELS 93
Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines 93
Synergistic activity of letrozole and sorafenib on MCF7/AROM-1 breast cancer cells 93
Effects of FGFR1 inhibition on survival, proliferation, and energy metabolism in Non Small Cell Lung Cancer (NSCLC) cell lines 92
Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells 92
Cancer of Unknown Primary: novel therapeutic opportunities from patient-derived cell cultures and in vivo models 91
The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells 87
Overcoming Palbociclib Resistance by Combined Treatment with PI3K/AKT/mTOR Inhibitors in Mesothelioma Cells 87
Multiple effects of CDK4/6 inhibition in cancer: From cell cycle arrest to immunomodulation 87
Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines 85
Effect of constitutive or inducible expression of the FHIT gene in a lung cancer cell line 84
Role of sphingolipid metabolism in osimertinib-resistance in EGFR-mutated NSCLC models 81
Modulazione della riespressione del gene FHIT in cellule di carcinoma polmonare 81
Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib 81
Impairing energy metabolism in solid tumors through agents targeting oncogenic signaling pathways 80
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones 78
Targeting oncogenic PI3K/Akt/mTOR pathway in squamous cell lung carcinoma 77
Targeting FGFR1 pathway in non small cell lung cancer both in vitro and in vivo 73
Immunotherapeutic approaches in malignant pleural mesothelioma 72
Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments 72
Effect of inducible FHIT and p53 expression on CALU-1 cell proliferation. 70
Synergic anti-proliferative effect of gefitinib and RAD001 in non small cell lung cancer cell lines 70
Effect of letrozole and sorafenib on cell proliferation and apoptosis of MCF-7/AROM-1 breast cancer cell line 69
Erlotinib potentiates Cetuximab-dependent call citotoxicity in EGFR wild type NSCLC cell lines 69
Synergistic activity of letrozole and sorafenib on breast cancer cells 68
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines 68
Increased level of inducible HSP70 in cells exposed to electromagnetic fields. 67
Functional characterization of gefitinib uptake in non-small cell lung cancer cell lines 67
Espressione Inducibile del gene FHIT in cellule di carcinoma polmonare 64
Studio dell’espressione del gene FHIT in cellule di carcinoma polmonare 62
Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer 61
Pure anti-tumor effect of zoledronic acid in naive bone-only metastatic and locally advanced breast cancer: proof from the "biological window therapy" 61
Targeting FGFR1 pathway in squamous cell lung cancer 61
New therapeutic strategies for malignant pleural mesothelioma 59
Reprogramming of Lipid Metabolism in Lung Cancer: An Overview with Focus on EGFR-Mutated Non-Small Cell Lung Cancer 57
Evaluation of gefitinib maintenance in an EGFR-mutant NSCL cell line with acquired resistance 55
Corrigendum: CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells (Frontiers in Oncology, (2022), 12, (942341), 10.3389/fonc.2022.942341) 45
Synergic activity of FGFR2 and MEK inhibitors in the treatment of FGFR2-amplified cancers of unknown primary 41
Intrinsic Resistance to Osimertinib in EGFR Mutated NSCLC Cell Lines Induced by Alteration in Cell-Cycle Regulators 35
Effect of inducible Fhit and p53 expression in Calu-1 lung cancer cell line 32
null 31
Effect of constitutive expression of the fragile histidine triad gene on non small cell lung cancer 26
Totale 8.106
Salva come PNG Salva come JPEG
Categoria #
all - tutte 30.300
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.300
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021552 13 49 38 37 59 16 48 30 86 23 113 40
2021/2022418 36 15 21 38 15 10 70 30 21 19 30 113
2022/20231.723 147 183 121 118 159 196 14 142 540 9 73 21
2023/2024812 38 51 29 43 55 157 68 72 33 45 89 132
2024/20252.479 87 112 169 179 252 267 179 127 287 201 211 408
2025/2026266 266 0 0 0 0 0 0 0 0 0 0 0
Totale 8.106